Vanguard Global Advisers’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
Other funds holding DYN
Vanguard Global Advisers's DYN Position: Q3 2026 in Review
Vanguard Global Advisers increased its Dyne Therapeutics (DYN) stake by 33% in Q3 2026, buying an estimated $409K and bringing the position to 71,924 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.
Vanguard Global Advisers first reported a position in DYN in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.2M in Q2 2026. 270 funds tracked by Wall St. Rank hold DYN as of Q3 2026.
- Vanguard Global Advisers held 71,924 shares of Dyne Therapeutics worth $1.16M as of Q3 2026.
- Vanguard Global Advisers bought 17,787 Dyne Therapeutics shares in Q3 2026, an estimated $409K.
- Dyne Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1627 holding.
- Vanguard Global Advisers first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Dyne Therapeutics position peaked at $1.2M in Q2 2026.
- 270 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.